

## Twitter Thread by Billy Bostickson ■■■&■ ■

Billy Bostickson ■■■&■ ■

@BillyBostickson



@EricTopol @NBA @StephenKissler @yhgrad 1. Reversion of molecularly engineered, partially attenuated, very virulent infectious bursal disease virus during infection of commercial chickens

<https://t.co/wOg1Ekl3Xp>

2. Reversion to Virulence of Attenuated Canine Distemper Virus In Vivo and In

@fapsid @EricTopol @NBA @StephenKissler @yhgrad 3. pathogenic reversion of simian immunodeficiency virus SIVmac239Deltanef increases viral replication

<https://t.co/jHmujgDVAC>

@fapsid @EricTopol @NBA @StephenKissler @yhgrad 4. Genetic suppression in reovirus: Ramig et al. 1977

papovavirus: Shortle et al. 1979

picornavirus: King et al. 1980

vaccinia virus: McFadden et al. 1980

influenza virus: Tolpin et al. 1981

herpesvirus: Hall and Almey 1982

adenovirus: Kruijer et al. 1983

<https://t.co/4zARJZWBzk>

@fapsid @EricTopol @NBA @StephenKissler @yhgrad 5. reversion to virulence of live attenuated vaccines

1. Evolutionary reversion of live viral vaccines: Can genetic engineering subdue it?

<https://t.co/9lY6ji88Gr>

2. Mechanisms Causing Reversion to Virulence in an Attenuated SARS-CoV

<https://t.co/ogvKaqiQj8>

@fapsid @EricTopol @NBA @StephenKissler @yhgrad 6. reversion to virulence of live attenuated vaccines

3. The double-edged sword: How evolution can make or break a live-attenuated virus vaccine

<https://t.co/jRJNTAR6tn>

4. Selection Versus Mutation: Reducing the Risk of Vaccine Reversion

<https://t.co/dkVs3wTkve>

[@fapsid](#) [@EricTopol](#) [@NBA](#) [@StephenKissler](#) [@yhgrad](#) 7. NSP16 mutant reverts in immune-compromised model and SARS-CoV dNSP16 can revert to virulence  
Menachery, Yount & Baric 2018  
Combination attenuation offers strategy for live-attenuated coronavirus vaccines  
<https://t.co/q2oQQzc1SG>

## **Combination attenuation offers strategy for live-attenuated coronavirus vaccines**

Vineet D. Menachery<sup>1,2</sup>, Lisa E. Gralinski<sup>2</sup>, Hugh D. Mitchell<sup>4</sup>, Kenneth H. Dinno III<sup>2</sup>, Sarah R. Leist<sup>2</sup>, Boyd L. Yount Jr.<sup>2</sup>, Eileen T. McAnarney<sup>1,2</sup>, Rachel L. Graham<sup>2</sup>, Katrina M. Waters<sup>4</sup>, Ralph S. Baric<sup>2,3</sup>.

<sup>1</sup>Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA

<sup>2</sup>Departments of Epidemiology and <sup>3</sup>Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

<sup>4</sup>Biological Sciences Division, Pacific Northwest National Laboratory, Richland, Washington, USA

**Corresponding Author:** Ralph S. Baric

**Address:** University of North Carolina at Chapel Hill, 2107 McGavran-Greenberg Hall  
CB 7435, Chapel Hill, NC 27599-7435

**Telephone:** 919-966-7991 **Fax:** 919-966-0584

**Email:** [Rbaric@email.unc.edu](mailto:Rbaric@email.unc.edu)

Running Title:

Keywords: coronavirus, SARS-CoV, MERS-CoV, vaccine, live-attenuated, aged